Company intelligence / Profile preview
Numab Therapeutics AG
Horgen, Zurich, Switzerlandnumab.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Numab Therapeutics AG develops multi-specific antibody-based immunotherapies targeting cancer and inflammatory diseases. Its proprietary MATCH™ and Lambda-Cap™ platforms enable rapid design of differentiated antibody therapeutics with improved potency, stability, duration, and safety. The company’s lead asset NM26—a bispecific antibody targeting IL‑4Rα/IL‑31RA for atopic dermatitis—was spun out into a subsidiary acquired by Johnson & Johnson in May–June 2024 for $1.25 billion prior to Phase II trials. Additional pipeline assets include multi-specifics like NM49 for oncology developed in partnership with Ono Pharmaceutical.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Multi-specific antibodiesBispecific antibodiesAntibody-based immunotherapies
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
Ono PharmaceuticalKaken PharmaceuticalEisaiBoehringer Ingelheim
Beyond the preview
Go deeper on Numab Therapeutics AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Numab Therapeutics AG.